首页> 外文期刊>Lab on a chip >Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform
【24h】

Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform

机译:迈向个性化医学:灌注微流体平台中患者肺癌细胞球体的化学敏感性测定

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cancer is responsible for millions of deaths worldwide and the variability in disease patterns calls for patient-specific treatment. Therefore, personalized treatment is expected to become a daily routine in prospective clinical tests. In addition to genetic mutation analysis, predictive chemosensitive assays using patient's cells will be carried out as a decision making tool. However, prior to their widespread application in clinics, several challenges linked to the establishment of such assays need to be addressed. To best predict the drug response in a patient, the cellular environment needs to resemble that of the tumor. Furthermore, the formation of homogeneous replicates from a scarce amount of patient's cells is essential to compare the responses under various conditions (compound and concentration). Here, we present a microfluidic device for homogeneous spheroid formation in eight replicates in a perfused microenvironment. Spheroid replicates from either a cell line or primary cells from adenocarcinoma patients were successfully created. To further mimic the tumor microenvironment, spheroid co-culture of primary lung cancer epithelial cells and primary pericytes were tested. A higher chemoresistance in primary co-culture spheroids compared to primary monoculture spheroids was found when both were constantly perfused with cisplatin. This result is thought to be due to the barrier created by the pericytes around the tumor spheroids. Thus, this device can be used for additional chemosensitivity assays (e.g. sequential treatment) of patient material to further approach the personalized oncology field.
机译:癌症是全球数百万人死亡的原因,疾病模式的变化要求针对患者的治疗。因此,在前瞻性临床测试中,个性化治疗有望成为日常工作。除基因突变分析外,还将使用患者细胞进行预测性化学敏感性分析,作为决策工具。但是,在将其广泛应用于临床之前,需要解决与建立此类测定法相关的若干挑战。为了最好地预测患者的药物反应,细胞环境需要类似于肿瘤的细胞环境。此外,从数量稀少的患者细胞中形成均质复制品对于比较各种条件(化合物和浓度)下的反应至关重要。在这里,我们介绍了一种微流体装置,用于在灌注的微环境中进行八次重复的均匀球体形成。已成功创建了来自腺癌患者的细胞系或原代细胞的球状体复制品。为了进一步模拟肿瘤微环境,测试了原发性肺癌上皮细胞和原发性周细胞的球状共培养。当两者都不断地用顺铂灌注时,与原代单培养球体相比,原代共培养球体的化学抗性更高。认为该结果归因于肿瘤球体周围的周细胞产生的屏障。因此,该装置可用于患者材料的其他化学敏感性测定(例如顺序治疗),以进一步接近个性化肿瘤领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号